Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • TNF-? production inhibitors
    Patent number: 7491739
    Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein “A” is —(NR4)—, —(CR5R6)— or —O—, “B” is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and “X” is oxygen or sulfer respectively.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: February 17, 2009
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
  • Therapeutic Agent for Keratoconjunctival Disorder
    Publication number: 20090042962
    Abstract: An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R1 represents a carboxy group or a substituted or unsubstituted nitrogen-containing 5-membered heterocyclic ring; and R2 and R3 may be the same or different and represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkylcarbonyl group.
    Type: Application
    Filed: April 21, 2006
    Publication date: February 12, 2009
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Keiichi Shibagaki, Shin-ichiro Hirai, Masatsugu Nakamura
  • Noninvasive Drug Delivery System To Tissue of Posterior Segment of Eye Using Solid Composition
    Publication number: 20090036552
    Abstract: The present invention provides a drug delivery system by noninvasive administration, which is excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue. By administering a solid composition comprising a drug and a mucoadhesive substance having an adhesion strength of from 200 to 1000 g in the conjunctival sac, a drug delivery system excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue can be constructed.
    Type: Application
    Filed: July 28, 2006
    Publication date: February 5, 2009
    Applicant: Santen Pharmaceutical Co. Ltd.
    Inventors: Koumei Okabe, Fumitaka Tasaka
  • Methods for treating a corneal disorder and promoting skin wound healing
    Publication number: 20090005317
    Abstract: A method for treating a corneal disorder or for promoting skin wound healing comprising administering to a patient in need thereof a composition containing pharmaceutically effective amounts of (i) a first peptide comprising an amino acid sequence containing the following consecutive amino acids: Ser-Ser-Ser-Arg (SEQ ID NO: 1), or an analog thereof or a pharmaceutically acceptable salt thereof and (ii) a second peptide comprising an amino acid sequence containing the following consecutive amino acids with a terminal —NH2 group: Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2), or an analog thereof or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 20, 2007
    Publication date: January 1, 2009
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., Teruo NISHIDA
    Inventors: Teruo Nishida, Makoto Inui, Masatsugu Nakamura
  • Delivering substance and drug delivery system using the same
    Patent number: 7455855
    Abstract: An object of the present invention is to prepare substances which are excellent in delivery and enable drugs to be retained in a body effectively over a long period and to construct a drug delivery system using the substances. When the delivering substance which is obtained by reacting polyalkylene glycol or a reactive derivative thereof, a phospholipid and a drug with each other to form covalent bonds is administered systemically or topically, the substance is retained at a target site in a body for a long period, thereby making it possible to sustain drug efficacy over a long period by a single administration.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: November 25, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Kuwano, Masaki Nakagawa, Hiroshi Suhara
  • Preventative Composition For Ophthalmic Use
    Publication number: 20080269353
    Abstract: An object of the present invention is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a chlorite. A liquid preparation for ophthalmic use containing a preservative composition for ophthalmic use comprising a chlorite and at least one stabilizer selected from the following 1) to 7): 1) creatinine; 2) geraniol; 3) glucose; 4) tocopherol acetate; 5) oxyquinoline sulfate; 6) a sugar alcohol; and 7) a polyoxyethylene sorbitan fatty acid ester can prevent the generation of chlorine dioxide, and is therefore excellent in safety and exhibits a sustained preservative effect for a prolonged period of time.
    Type: Application
    Filed: July 13, 2006
    Publication date: October 30, 2008
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koichi Takada, Akio Kimura, Mikiko Okemoto
  • Open instillation container and method of manufacturing the container
    Patent number: 7438704
    Abstract: A bottomed conical hollow 6b is formed in a tip end of the container body A formed of a thermoplastic material with a liquid filled and sealed therein simultaneously during the molding process, the hollow having an inside diameter enlarging toward the tip end, and a small-diameter instilling hole 6c is penetrated through the bottom of the hollow 6b for controlling, at a set quantity, the liquid pushed out of the container body A.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: October 21, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Yoichi Kawashima, Yukio Kusu
  • Eyedrops containing particulate agar
    Publication number: 20080199524
    Abstract: It is intended to prepare a composition which contains polysaccharide at a high concentration and yet remains in the state of a liquid having low viscosity to thereby provide drugs, eyedrops, foods, cosmetics, toiletry products having a novel texture or function. The composition in the state of a liquid having low viscosity is obtained by heating polysaccharide at a high concentration in a water-containing liquid and then cooling under applying a shear force, which enables the provision of the above-described drugs. The composition is usable as an aqueous drug vehicle which is free from gelling due to temperature changes during storage and easily applied without pouring and/or streaming down. Eyedrops containing agar have an effect of enhancing ocular drug penetration. Eyedrops containing particulate agar maintain a low viscosity and, achieve easy instillation and impart a favorable feel in instillation.
    Type: Application
    Filed: June 6, 2007
    Publication date: August 21, 2008
    Applicants: TORAY INDUSTRIES, INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Inohara, Masahito Yoshikawa, Takashi Taniguchi, Mitsuru Yokota, Naoki Shimoyama, Masaki Ue, Miho Araki, Yukiko Sugihara, Yoshihide Horibe, Mitsuaki Kuwano
  • Method for treating pain or pruritis by administering ?-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
    Patent number: 7410987
    Abstract: A method of treating pain or pruritis comprising administering to a patient in need thereof a pharmaceutically effective amount of a ? opioid receptor agonist of the formula wherein R is an alkyl having an amino group as a substituent; and R1 is acyl.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: August 12, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Maki Tokai, Takahiro Honda, Masashi Niwa, Yaeko Osumi, Ken-ichi Fujimura, Shin-ichi Kohno
  • TNF-alpha production inhibitors
    Publication number: 20080182881
    Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein A is —(NR4)—, —(CR5R6)— or —O—, B is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.
    Type: Application
    Filed: August 15, 2007
    Publication date: July 31, 2008
    Applicant: SANTEN PHARMACEUTICAL, CO., LTD.
    Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
  • Angiogenesis inhibitors
    Publication number: 20080161270
    Abstract: An object of the present invention is to find new pharmacological actions of urea compounds having structure represented by the general formula [1]. The urea compounds having the structure represented by the general formula [1] have excellent angiogenesis inhibitory actions. [wherein “A” is —(NR4)—, —(CR5R6)— or —O—, “B” is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantylalkyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfur.
    Type: Application
    Filed: January 25, 2008
    Publication date: July 3, 2008
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hidehito Matsuoka, Kazuo Nishimura, Hisayuki Seike, Hiroyuki Aono, Masaaki Murai
  • Product Containing Prostaglandin Having Fluorine Atom In Its Molecule
    Publication number: 20080139648
    Abstract: An object of the present invention is to provide a prostaglandin-containing product, wherein when an aqueous liquid preparation containing a prostaglandin derivative having at least a fluorine atom in its molecule as an active ingredient is stored in a resin container subjected to a sterilization treatment, a decrease in the content of the prostaglandin derivative in the aqueous liquid preparation can be inhibited. The aqueous liquid preparation containing the prostaglandin derivative having at least a fluorine atom in its molecule as an active ingredient is stored in the resin container subjected to a sterilization treatment with ethylene oxide gas. By doing this, a decrease in the content of the prostaglandin derivative in the aqueous liquid preparation can be inhibited.
    Type: Application
    Filed: December 9, 2005
    Publication date: June 12, 2008
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Takehiro Kado, Tomoyuki Okamoto, Hiroyuki Asada, Akio Kimura
  • Therapeutic agent for keratoconjunctival disorder
    Patent number: 7358255
    Abstract: Object of the present invention is to search a novel pharmaceutical use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione being a condensed heterocyclic compound, or a salt thereof. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a salt thereof can exert an excellent effect to promote healing in a dry eye model, and is useful as a therapeutic agent for keratoconjunctival disorders such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: April 15, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatsugu Nakamura, Shin-ichiro Hirai
  • Therapeutic agent for keratoconjunctival disorder
    Patent number: 7348329
    Abstract: An object of the present invention is to discover a new medicinal use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine. Both of the compounds exert an excellent improving effect on corneal disorder models and is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: March 25, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatsugu Nakamura, Shin-ichiro Hirai
  • Therapeutic Agent for Keratoconjunctival Disorder
    Publication number: 20080070958
    Abstract: An object of the present invention is to research a new medicinal use of E-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino]-4-phenylbutyric acid, Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid, 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy] benzoic acid, 2(S)-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl] propionic acid, or a salt thereof. Any of the above-mentioned carboxylic acid compounds and a salt thereof exhibit an excellent improving effect on corneal disorder models and are useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis or filamentary keratitis.
    Type: Application
    Filed: September 13, 2005
    Publication date: March 20, 2008
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatsugu Nakamura, Shin-ichiro Hirai, Keiichi Shibagaki
  • TNF-? production inhibitors
    Patent number: 7345064
    Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein A is —(NR4)—, —(CR5R6)— or —O—, B is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: March 18, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
  • Hole inspection system for a pierced container
    Patent number: 7325440
    Abstract: A hole inspection system for a pierced container 1 for inspecting an outwardly opened hole 1a formed in a flexible container 1 for performing a proper inspection for the size of the hole 1a of the flexible pierced container 1. The flexible container 1 is pressed from outside to blow out the gas A present within the container through the hole 1a thereby to detect a jet pressure of the gas blown out through the hole 1a by the pressing operation and to determine the size of the hole 1a by comparing a detected value of the jet pressure in a predefined period while the jet pressure is rising with an upper limit pressure value corresponding to a maximum size of the hole 1a and a lower limit pressure value corresponding to a minimum size of the hole 1a.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: February 5, 2008
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kozo Minamitani, Hitoshi Okino
  • Novel cyclic compound having quinolylalkylthio group
    Publication number: 20080021064
    Abstract: The present invention relates to a synthesis study of novel cyclic compounds having a quinolylalkylthio group represented by the formula (1), and pharmacological actions of the compounds. In the formula, the ring X represents: which may have halogen and/or alkyl; R1 and R2 independently represent hydrogen, alkyl, cycloalkyl, aryl or a (non) aromatic heterocycle; R3 represents qinolyl; A represents sulfur, sulfinyl or sulfonyl; and B represents alkylene.
    Type: Application
    Filed: August 30, 2007
    Publication date: January 24, 2008
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Takahiro Honda, Hisashi Tajima, Kazuyoshi Okamoto, Minoru Yamamoto
  • Liquid container
    Publication number: 20070267435
    Abstract: A liquid container comprising a container body 1 including a liquid storage space formed therein, and an instilling opening member 2, wherein the liquid container further comprises a sealing portion 5 for hermetically confining liquid in the interior of the container body 1, an unsealing member 6 for opening the sealing portion 5, and a check valve 4 provided at a portion closer to the liquid storage space than the sealing portion 5 and the unsealing member 6 for allowing the unsealing member 6 to open the sealing portion 5 when the instilling opening member 2 is pushed toward the container body 1, and for preventing the liquid from flowing back to the interior of the container body 1.
    Type: Application
    Filed: March 9, 2005
    Publication date: November 22, 2007
    Applicant: Santen Pharmaceutical Co., Ltd
    Inventors: Hiroshi Yamada, Naohito Miyoshi
  • Viscous Agent for Ophthalmic Use
    Publication number: 20070270378
    Abstract: An object of the present invention is to provide an eyedrop which has a relatively low viscosity before instillation but is thickened on the eyeball surface at instillation. The eyedrop containing a viscous agent for ophthalmic use, which comprises a combination of hydroxyethylcellulose and dextran, exhibits a specific and synergistic thickening effect in the coexistence of mucin. Therefore, the eyedrop of the present invention is thickened on the eyeball surface upon contact with mucin in the precorneal tear film at instillation, whereby a desired pharmacological efficacy or refreshing feel can be sustained.
    Type: Application
    Filed: May 27, 2005
    Publication date: November 22, 2007
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Kayoko Sakamoto, Akio Kimura, Shin-Ichiro Hirai, Masatsugu Nakamura